New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
11:49 EDTCRR, TUP, TER, ONCY, GNCHigh option volume stocks: GNC TER CRR ONCY TUP
News For GNC;TER;CRR;ONCY;TUP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
13:44 EDTGNCVitamin Shoppe jumps after Carlson discloses 5% stake
The shares of Vitamin Shoppe (VSI) are climbing after asset management firm Carlson Capital revealed that it had obtained a 5.34% stake in the company and said that it had held talks with the retailer of natural treatments, supplements and vitamins. WHAT'S NEW: Carlson disclosed its stake in the company in an SEC filing and said that it had held talks with the company's board about a number of matters, including the company’s business, management and strategic alternatives and direction. Carlson said it would continue to hold talks with the company, and others, about these issues. WHAT'S NOTABLE: Vitamin Shoppe reported last October that it had spoken to investment banks about retaining a financial adviser, Reuters reported at the time. The retailer had come under pressure to consider selling the company, added the news service. In February, New York's attorney general accused a Vitamin Shoppe competitor, GNC (GNC) of selling products whose content did not match their labels. Vitamin Shoppe's CEO said that, despite the fact that it was not targeted by the attorney general, it saw a slight impact on its sales from the news, according to trade website NUTRA ingredients-usa.com. PRICE ACTION: In mid-afternoon trading, Vitamin Shoppe jumped 10.7% to $43.12, while GNC gained 2.8% to $47.25.
12:18 EDTGNCCarlson Capital reports 5.34% stake in Vitamin Shoppe, says plans more talks
Subscribe for More Information
07:09 EDTTUPTupperware Brands sees FY15 Europe sales to be about even
Subscribe for More Information
07:08 EDTTUPTupperware Brands sees weaker rates for Venezuelan bolivar affecting FY15
For full year 2015, of the $1.13 negative year-over-year impact of changes in rates on diluted earnings per share, 28c relates to weaker rates for the Venezuelan bolivar. Assuming that the current Simadi exchange rate of approximately 195.0 continues in 2015, there will be a negative translation impact from Venezuela on the company's second quarter sales comparisons of 3.3 percentage points and 2.3 percentage points on the full year comparison, and a negative impact on the diluted earnings per share comparisons with 2014 in the second quarter, and full year of 13c, and 28c, respectively. Second quarter 2014 sales and segment profit in Venezuela were $24M and $9M, respectively. In the second half of 2014, sales and segment profit in Venezuela were $10M and $1.4M respectively.
07:05 EDTTUPTupperware Brands sees FY15 adjusted EPS $4.60-$4.70, consensus $4.80
Subscribe for More Information
07:05 EDTTUPTupperware Brands sees Q2 adjusted EPS $1.14-$1.19, consensus $1.23
Subscribe for More Information
07:03 EDTTUPTupperware Brands reports Q1 adjusted EPS $1.02, consensus 98c
Subscribe for More Information
April 21, 2015
15:28 EDTTUPNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
April 20, 2015
06:36 EDTONCYOncolytics announces series of posters to be made at AACR Annual Meeting
Subscribe for More Information
April 17, 2015
06:31 EDTONCYOncolytics receives ODD by FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted an Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of malignant glioma. The company applied for an ODD for pediatric high grade gliomas, or HGG, however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages. In three previous brain cancer studies including gliomas, Reolysin has been shown to infect a variety of brain tumors when delivered intravenously.
April 16, 2015
09:14 EDTONCYOncolytics granted orphan status for malignant glioma treatment
The FDA granted Oncolytics orphan status for its treatment of malignant glioma, Reolysin. .
April 15, 2015
06:35 EDTONCYOncolytics Biotech's Reolysin shows positive results in pancreatic cancer
Subscribe for More Information
06:34 EDTONCYOncolytics Biotech presents Reolysin data at UK Immuno-oncology meeting
Oncolytics Biotech announced that Dr. Matt Coffey, COO, made a presentation titled "Reolysin and Immune Therapy: Rationale for Combination Therapy" at the Royal Society of Medicine's Immuno-oncology: Using the Body's Own Weapons conference, held in London, UK. The presentation included data from a single arm clinical study examining the use of Reolysin in combination with gemcitabine in patients with advanced pancreatic cancer, PD-1 and PD-L1 up regulation data from a single arm clinical study examining the use of Reolysin in patients with primary glioblastomas or brain metastases, as well as preclinical data. Highlights of new data presented include: Clinical evidence that Reolysin treatment results in immunological changes to both the tumor cells and the tumor microenvironment that is conducive to novel immune targeting interventions; and Updated results from the REO 017 study, in which pancreatic cancer patients received combination therapy with Reolysin and gemcitabine demonstrated a median overall survival of 10.2 months, and one- and two-year survival rates of 45% and 24%, respectively.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use